The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day.
【저자키워드】 COVID-19, severe acute respiratory syndrome coronavirus 2, therapy, pemphigus, 【초록키워드】 Treatment, pandemic, COVID-19 pandemic, Epidemics, drug, Novel coronavirus, immunosuppressive drugs, Autoimmune disease, COVID-19 outbreak, outbreak, Patient, underlying conditions, Evidence, pemphigus vulgaris, mucous membranes, acquisition, auto-immune disease, Course, raised, susceptible patient, 【제목키워드】 review, article,